79 related articles for article (PubMed ID: 28601509)
1. Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy.
Yuan Z; Chen S; Sun Q; Wang N; Li D; Miao S; Gao C; Chen Y; Tan C; Jiang Y
Bioorg Med Chem; 2017 Aug; 25(15):4100-4109. PubMed ID: 28601509
[TBL] [Abstract][Full Text] [Related]
2. Molecular design, synthesis and
Abdel-Atty MM; Farag NA; Serya RAT; Abouzid KAM; Mowafy S
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1290-1312. PubMed ID: 34187263
[TBL] [Abstract][Full Text] [Related]
3. PD-1/PD-L1 checkpoint inhibitors in combination with olaparib display antitumor activity in ovarian cancer patient-derived three-dimensional spheroid cultures.
Appleton KM; Elrod AK; Lassahn KA; Shuford S; Holmes LM; DesRochers TM
Cancer Immunol Immunother; 2021 Mar; 70(3):843-856. PubMed ID: 33492447
[TBL] [Abstract][Full Text] [Related]
4. Three-component Castagnoli-Cushman reaction with ammonium acetate delivers 2-unsubstituted isoquinol-1-ones as potent inhibitors of poly(ADP-ribose) polymerase (PARP).
Safrygin A; Zhmurov P; Dar'in D; Silonov S; Kasatkina M; Zonis Y; Gureev M; Krasavin M
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1916-1921. PubMed ID: 34461785
[TBL] [Abstract][Full Text] [Related]
5. Enhanced Anti-Cancer Effect of Folate-Conjugated Olaparib Nanoparticles Combined with Radiotherapy in Cervical Carcinoma.
Li D; Hu C; Yang J; Liao Y; Chen Y; Fu SZ; Wu JB
Int J Nanomedicine; 2020; 15():10045-10058. PubMed ID: 33328733
[TBL] [Abstract][Full Text] [Related]
6. New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma.
Meneceur S; De Vos CE; Petzsch P; Köhrer K; Niegisch G; Hoffmann MJ
J Cell Mol Med; 2024 May; 28(9):e18342. PubMed ID: 38693852
[TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis, In Vitro Anticancer Evaluation and Molecular Modelling Studies of 3,4,5-Trimethoxyphenyl-Based Derivatives as Dual EGFR/HDAC Hybrid Inhibitors.
Ibrahim TS; Malebari AM; Mohamed MFA
Pharmaceuticals (Basel); 2021 Nov; 14(11):. PubMed ID: 34832959
[TBL] [Abstract][Full Text] [Related]
8. Rational Design of PARP1/c-Met Dual Inhibitors for Overcoming PARP1 Inhibitor Resistance Induced by c-Met Overexpression.
Sun Z; Li L; Zhai B; Hu M; Huang L; Huang S; Ye L; Kong X; Xu J; Bai J; Yan J; Zhou Q; Hu Z; Zhang Y; Jiang Y; Zhang Y; Qiao Z; Zou Y; Xu Y; Zhu Q
J Med Chem; 2024 Mar; 67(6):4916-4935. PubMed ID: 38477575
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of matrine contains benzimidazole derivatives as dual TOPOI and PARP inhibitors for cancer therapy.
Qiu G; Xie J; Li F; Han K; Long Q; Kowah JAH; Gao R; Wang L; Liu X
Eur J Med Chem; 2024 Apr; 270():116348. PubMed ID: 38554475
[TBL] [Abstract][Full Text] [Related]
10. Discovery of pyrano[2,3-
Abd El-Sattar NEA; Badawy EHK; Elrazaz EZ; Ismail NSM
RSC Adv; 2021 Jan; 11(8):4454-4464. PubMed ID: 35424391
[TBL] [Abstract][Full Text] [Related]
11. Leveraging a rationally designed veliparib-based anilide eliciting anti-leukemic effects for the design of pH-responsive polymer nanoformulation.
Thakur A; Chu YH; Rao NV; Mathew J; Grewal AS; Prabakaran P; Guru S; Liou JP; Pan CH; Nepali K
Eur J Med Chem; 2024 May; 273():116507. PubMed ID: 38776806
[TBL] [Abstract][Full Text] [Related]
12. Design of Selective PARP-1 Inhibitors and Antitumor Studies.
Zhang Y; Li X; Liu F; Bai X; Liu X; Sun H; Gao C; Lin Y; Xing P; Zhu J; Liu R; Wang Z; Dai J; Shi D
J Med Chem; 2024 May; ():. PubMed ID: 38776379
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic and Antiproliferative Activity of LASSBio-2208 and the Attempts to Determine Its Drug Metabolism and Pharmacokinetics In Vitro Profile.
Pillpe-Meza RM; Gouveia WL; Barbosa G; Fraga CAM; Barreiro EJ; Lima LM
Pharmaceuticals (Basel); 2024 Mar; 17(3):. PubMed ID: 38543175
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Advances and New Directions for Triple-Negative Breast Cancer.
Andreopoulou E; Kelly CM; McDaid HM
Breast Care (Basel); 2017 Mar; 12(1):21-28. PubMed ID: 28611537
[TBL] [Abstract][Full Text] [Related]
15. A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment.
Bednar EM; Oakley HD; Sun CC; Burke CC; Munsell MF; Westin SN; Lu KH
Gynecol Oncol; 2017 Aug; 146(2):399-404. PubMed ID: 28610746
[TBL] [Abstract][Full Text] [Related]
16. Chemosensitivity of BRCA1-Mutated Ovarian Cancer Cells and Established Cytotoxic Agents.
van Haaften C; van Eendenburg J; Boot A; Corver WE; Haans L; van Wezel T; Trimbos JB
Int J Gynecol Cancer; 2017 Oct; 27(8):1571-1578. PubMed ID: 28604461
[TBL] [Abstract][Full Text] [Related]
17. Targeting DNA repair and replication stress in the treatment of ovarian cancer.
Murai J
Int J Clin Oncol; 2017 Aug; 22(4):619-628. PubMed ID: 28643177
[TBL] [Abstract][Full Text] [Related]
18. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Pujade-Lauraine E; Ledermann JA; Selle F; Gebski V; Penson RT; Oza AM; Korach J; Huzarski T; Poveda A; Pignata S; Friedlander M; Colombo N; Harter P; Fujiwara K; Ray-Coquard I; Banerjee S; Liu J; Lowe ES; Bloomfield R; Pautier P;
Lancet Oncol; 2017 Sep; 18(9):1274-1284. PubMed ID: 28754483
[TBL] [Abstract][Full Text] [Related]
19. Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.
Chen W; Guo N; Qi M; Dai H; Hong M; Guan L; Huan X; Song S; He J; Wang Y; Xi Y; Yang X; Shen Y; Su Y; Sun Y; Gao Y; Chen Y; Ding J; Tang Y; Ren G; Miao Z; Li J
Eur J Med Chem; 2017 Sep; 138():514-531. PubMed ID: 28692916
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
